Create is expected to achieve double-digit year-over-year revenue growth in Q1, excluding nonstrategic revenue, with a ...
BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results